Abstract
Chromosomal microarray (CMA) has enabled the detection of clinically significant copy number variants (CNVs) that are otherwise below the detection limit of conventional cytogenetics. It is well documented that CMA using microarrays with exonic coverage of disease genes allows the detection of small clinically relevant exonic CNVs. In 2016, the American Congress of Obstetricians and Gynecologist (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) jointly recommended CMA as the first-tier test in the diagnostic evaluation of a patient with a fetus having 1 or more abnormal findings on ultrasound, and in cases of intrauterine fetal death or stillbirth.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.